⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Official Title: A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer

Study ID: NCT00617669

Conditions

Prostate Cancer

Study Description

Brief Summary: Enthuse M1C is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in combination with docetaxel (Taxotere) in patients with metastatic hormone resistant prostate cancer (HRPC). This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can further improve survival compared with docetaxel alone. ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin A receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer patients with bone metastases compared with docetaxel. All patients participating in this clinical trial will receive docetaxel chemotherapy, which is a commonly used chemotherapy to treat prostate cancer in addition to other existing prostate cancer therapies. Half the patients will receive ZD4054 (Zibotentan), and half the patients will receive placebo in addition to docetaxel and other prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may further slow the progression of the tumour. No patients will be deprived of standard prostate cancer therapy.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

Research Site, Greenbrae, California, United States

Research Site, San Diego, California, United States

Research Site, Norwich, Connecticut, United States

Research Site, Washington, District of Columbia, United States

Research Site, Fort Myers, Florida, United States

Research Site, Gainsville, Florida, United States

Research Site, Ocala, Florida, United States

Research Site, PORTUGALt St. Lucie, Florida, United States

Research Site, Rockville, Maryland, United States

Research Site, Minneapolis, Minnesota, United States

Research Site, Lincoln, Nebraska, United States

Research Site, Omaha, Nebraska, United States

Research Site, Chapel Hill, North Carolina, United States

Research Site, Durham, North Carolina, United States

Research Site, Winston-Salem, North Carolina, United States

Research Site, Canton, Ohio, United States

Research Site, Cincinnati, Ohio, United States

Research Site, Pittsburgh, Pennsylvania, United States

Research Site, Charleston, South Carolina, United States

Research Site, Chattanooga, Tennessee, United States

Research Site, Nashville, Tennessee, United States

Research Site, San Antonio, Texas, United States

Research Site, Richmond, Virginia, United States

Research Site, Seattle, Washington, United States

Research Site, Milwaukee, Wisconsin, United States

Research Site, Bahia Blanca, Buenos Aires, Argentina

Research Site, Buenos Aires, , Argentina

Research Site, Santa Fe, , Argentina

Research Site, Darlinghurst, New South Wales, Australia

Research Site, St Leonards, New South Wales, Australia

Research Site, Wollongong, New South Wales, Australia

Research Site, Redcliffe, Queensland, Australia

Research Site, Ashford, South Australia, Australia

Research Site, Footscray, Victoria, Australia

Research Site, Wodonga, Victoria, Australia

Research Site, Perth, Western Australia, Australia

Research Site, Subiaco, Western Australia, Australia

Research Site, Fortaleza, Ceara/ LA, Brazil

Research Site, Goiania, Goias/ LA, Brazil

Research Site, Goiania, Goias, Brazil

Research Site, Belo Horizonte, Minas GERMANYais, Brazil

Research Site, Curitiba, Parana/ Brazil, Brazil

Research Site, Londrina, PR, Brazil

Research Site, PORTUGALto Alegre, Rio Grande do Sul/ LA, Brazil

Research Site, Rio de Janeiro, RJ, Brazil

Research Site, Ribeirao Preto, Sao Paulo/ LA, Brazil

Research Site, Santo Andre, Sao Paulo, Brazil

Research Site, Sao Paulo, , Brazil

Research Site, Winnipeg, Manitoba, Canada

Research Site, Halifax, Nova Scotia, Canada

Research Site, London, Ontario, Canada

Research Site, Toronto, Ontario, Canada

Research Site, Quebec City, Quebec, Canada

Research Site, Sherbrooke, Quebec, Canada

Research Site, Brno, CZECHOSLOVAKIA Republic, Czech Republic

Research Site, Jablonec nad Nisou, , Czech Republic

Research Site, Kromeriz, , Czech Republic

Research Site, Olomouc, , Czech Republic

Research Site, Prague 2, , Czech Republic

Research Site, Prague 6, , Czech Republic

Research Site, Usti nad Labem, , Czech Republic

Research Site, Helsinki, , Finland

Research Site, Joensuu, , Finland

Research Site, Seinajoki, , Finland

Research Site, La Roche sur Yon, FRANCEnce, France

Research Site, Marseille, FRANCEnce, France

Research Site, Paris, FRANCEnce, France

Research Site, Reims, FRANCEnce, France

Research Site, Villejuif, FRANCEnce, France

Research Site, Paris, , France

Research Site, Saint Herblain, , France

Research Site, Hannover, GERMANYmany, Germany

Research Site, Berlin, , Germany

Research Site, Bonn, , Germany

Research Site, Dresden, , Germany

Research Site, Emmendingen, , Germany

Research Site, Kirchheim-Teck, , Germany

Research Site, Leipzig, , Germany

Research Site, Luebeck, , Germany

Research Site, Muenster, , Germany

Research Site, Tuebingen, , Germany

Research Site, Wuppertal, , Germany

Research Site, Budapest, HUNGARYary, Hungary

Research Site, Gyor, HUNGARYary, Hungary

Research Site, Miskolc, HUNGARYary, Hungary

Research Site, Ny Regyh Za, HUNGARYary, Hungary

Research Site, Szeged, HUNGARYary, Hungary

Research Site, Bangalore, Karnataka, India

Research Site, Trivandrum, Kerala, India

Research Site, Bhopal, Madhya Pradesh, India

Research Site, Pune, Maharashtra, India

Research Site, Bikaner, Rajasthan, India

Research Site, Jaipur, Rajasthan, India

Research Site, Vellore, Tamil Nadu, India

Research Site, Kolkata, West Bengal, India

Research Site, Kolkota, West Bengal, India

Research Site, Delhi, , India

Research Site, New Delhi, , India

Research Site, Genoa, , Italy

Research Site, Lugo (RA), , Italy

Research Site, Rome, , Italy

Research Site, Cheongju, Chungbuk, Korea, Republic of

Research Site, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of

Research Site, Nowon-gu, Seoul, Korea, Republic of

Research Site, Seodaemun-gu, Seoul, Korea, Republic of

Research Site, Songpa-gu, Seoul, Korea, Republic of

Research Site, Nijmegen, , Netherlands

Research Site, Cercado de Arequipa, Arequipa, Peru

Research Site, Cercado, Arequipa, Peru

Research Site, Callao, , Peru

Research Site, Lima, , Peru

Research Site, Lublin, POLANDand, Poland

Research Site, Swidnica, POLANDand, Poland

Research Site, Warszaa, POLANDand, Poland

Research Site, Koscierzyna, , Poland

Research Site, Wroclaw, , Poland

Research Site, Coimbra, PORTUGALtugal, Portugal

Research Site, PORTUGALto, PORTUGALtugal, Portugal

Research Site, Bucharest, , Romania

Research Site, Sibiu, , Romania

Research Site, Timisoara, , Romania

Research Site, Barnaul, RUSSIAsia, Russian Federation

Research Site, Izhevsk, RUSSIAsia, Russian Federation

Research Site, Kursk, RUSSIAsia, Russian Federation

Research Site, Sochi, RUSSIAsia, Russian Federation

Research Site, Voronezh, RUSSIAsia, Russian Federation

Research Site, Belgrade, SERBIAbia, Serbia

Research Site, Beograd, SERBIAbia, Serbia

Research Site, Nis, SERBIAbia, Serbia

Research Site, Panorama, Cape Town, South Africa

Research Site, TyGERberg, Cape Town, South Africa

Research Site, Overport, Durban, South Africa

Research Site, Bloemfontein, , South Africa

Research Site, PORt Elizabeth, , South Africa

Research Site, Madrid, , Spain

Research Site, Valencia, , Spain

Research Site, Stockholm, , Sweden

Research Site, Uppsala, , Sweden

Research Site, Aarau, , Switzerland

Research Site, Locarno, , Switzerland

Research Site, Sursee, , Switzerland

Research Site, Kaohsiung, TAIWANwan, Taiwan

Research Site, TAIWANpei, TAIWANwan, Taiwan

Research Site, Reading, Berkshire, United Kingdom

Research Site, Westgate Road, Newcastle Upon Tyne, United Kingdom

Research Site, London, , United Kingdom

Research Site, Manchester, , United Kingdom

Contact Details

Name: Karim Fizazi, MD, PhD

Affiliation: Gustave Roussy, Cancer Campus, Grand Paris

Role: PRINCIPAL_INVESTIGATOR

Name: Judd W Moul, MD, FACS

Affiliation: Duke University

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: